Evaluation of brand, ceiling and generic price differences in anti-epileptic drugs marketed in India: a novel cost variation analysis
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20251842Keywords:
Anti-epileptic drugs, Cost variation, Current index of medical specialties, Drugs prices control order, Jan aushadhi scheme, Inhibitors pharmacoeconomicsAbstract
Background: Epilepsy affects 6–10 million people in India, where over 60% of healthcare spending is out-of-pocket. Wide price differences in branded antiepileptic drugs (AEDs) can hinder adherence and increase financial burden. While DPCO sets ceiling prices and Jan Aushadhi offers low-cost generics, no Indian study has compared AED prices across both schemes. To assess price variation among 17 commonly used AEDs and compare brand prices with DPCO ceilings and Jan Aushadhi rates.
Methods: A cross-sectional cost analysis was conducted using MRPs from the Current Index of Medical Specialties, NPPA database and Jan Aushadhi Scheme database. Price variation and ratios were calculated. Median brand prices were benchmarked against DPCO and JAS prices to evaluate cost gaps.
Results: Pregabalin 75 mg capsules showed the highest inter-brand cost variation (564.7%), followed by pregabalin 150 mg tablets (487.9%) and levetiracetam 750 mg tablets (370.4%). Phenytoin 300 mg ER tablets were priced 39.63% above the DPCO ceiling and sodium valproate 200 mg tablets exceeded it by 36.7%. Branded AEDs were 0.7 to 8 times costlier than Jan Aushadhi generics; pregabalin 75 mg capsules were 667.73% more expensive.
Conclusions: This first dual-layered analysis of AED pricing in India shows wide price variation and poor compliance with controls. Expanding DPCO coverage, promoting generics and educating prescribers on drug costs can improve affordability and adherence.
Metrics
References
Govil N, Chahal S, Gupta N, Kaloti AS, Nadda A, Singh P. Factors associated with poor antiepileptic drug adherence in below poverty line persons with epilepsy: A cross-sectional study. J Neurosci Rural Pract. 2021;12(1):95–101. DOI: https://doi.org/10.1055/s-0040-1721200
World Health Organization. Epilepsy. 2024. Available at: https://www.who.int/news. Accessed on 21 February 2025.
Sinha A, Bhaumik D, Bhattacharyya N, others. Treatment expenditure pattern of epileptic patients: A study from a tertiary care hospital, Kolkata, India. Neurol Res Int. 2014;2014:1–6. DOI: https://doi.org/10.1155/2014/869572
Kandra N, Rajesh B. Cost variation analysis of different brands of oral antiepileptic drugs available in India. Int J Basic Clin Pharmacol. 2021;10(8):3278–82. DOI: https://doi.org/10.18203/2319-2003.ijbcp20212923
Sriram SS, Albadrani M. Impoverishing effects of out-of-pocket healthcare expenditures in India. J Family Med Prim Care. 2022;11(11):4206–12. DOI: https://doi.org/10.4103/jfmpc.jfmpc_590_22
Kaur S. Generic prescribing in India: a stumbling block. Int J Res Med Sci. 2020;8(9):3426–31. DOI: https://doi.org/10.18203/2320-6012.ijrms20203707
Atal S, Atal S, Deshmankar B, Nawaz SA. Cost analysis of commonly used drugs under price control in India: assessing the effect of drug price control order on brand price variation. Int J Pharm Pharm Sci. 2016;8(4):315–21.
Ray A, Najmi A, Khandelwal G, Sadasivam B. A Cost Variation Analysis of Drugs Available in the Indian Market for the Management of Thromboembolic Disorders. Cureus. 2020;12(5):1–16. DOI: https://doi.org/10.7759/cureus.7964
Joshi D, Gupta S, Singh TG, Prashar A, Gauniyal S, Singh SK. A study of various existing interventions for the treatment of hypertension in the Indian market under the Jan Aushadhi Scheme: A price control aspect for consideration. J Health Policy Outcomes Res. 2022;20(1):37–52. DOI: https://doi.org/10.7365/JHPOR.2022.1.4
Sai NP, Vedavathi H. Cost analysis study of price variation among the various brands of antiepileptics available in India. Int J Basic Clin Pharmacol. 2017;6(2):316–21. DOI: https://doi.org/10.18203/2319-2003.ijbcp20170342
R D, A G. Cost variation analysis of various brands of anticoagulants, fibrinolytics and antiplatelet drugs currently available in Indian pharmaceutical market. Natl J Physiol Pharm Pharmacol. 2019;9(5):368–72. DOI: https://doi.org/10.5455/njppp.2019.9.0205602032019
Shah A, Patel C, Shah P, Patel J, Sojitra B, Pandya S, et al. An Analysis of the Cost Variation Among Different Antimicrobial Agents: The Indian Scenario. Cureus. 2024;2:643. DOI: https://doi.org/10.7759/cureus.64538
National Pharmaceutical Pricing Authority. Revised ceiling price (WPI adjusted) of 748 scheduled formulations of Schedule-I (NLEM 2022) under Drugs (Prices Control) Order. 2013. Available from: https://www.nppaindia.nic.in. Accessed on 22 December 2024.
Pharmaceuticals & medical devices bureau of India. Jan Aushadhi Product Portfolio. Janaushadhi. 2024. Available at: https://janaushadhi.gov.in. Accessed on 22 February 2025.
Agrawal M, Kumar T, Mujumdar S, Saulat A. Pharmacoeconomic study of various brands of anti-epileptic drugs available currently in India. Asian J Pharma Clin Res.2024;17(2):135–7. DOI: https://doi.org/10.22159/ajpcr.2024.v17i2.50310
Allisabanavar SA. Cost variation analysis of various brands of anti-epileptic drugs currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2017;6(7):1666–9. DOI: https://doi.org/10.18203/2319-2003.ijbcp20172727
Wagle L, Swammy M K, Kempegowda MB. Cost variation study of antiepileptic drugs available in India. Asian J Pharma Clin Res. 2016;9:64–8.
Arya P, Kumar R, Chandra A, Mohan L. Study of price variations of anti-epileptic drugs available in different brands in Indian pharmaceutical market. Int J Res Med Sci. 2018;6(12):4102–5. DOI: https://doi.org/10.18203/2320-6012.ijrms20184914
Phatak AM, Hotwani JH, DeshmukhKiran R, Panchal SS, Naik MS. Cost analysis of long established and newer oral antiepileptic drugs available in The Indian Market. International J Med Res Health Sci. 2015;4(4):744–8. DOI: https://doi.org/10.5958/2319-5886.2015.00145.9
Parekh NV, George RS, Dharmadhikari A, Srivastava K, Panda BK. Study of clinical efficacy, safety and tolerability of low cost branded generic antiepileptic drugs in children and adolescents. Int J Basic Clin Pharmacol. 2019;8(8):1728–33. DOI: https://doi.org/10.18203/2319-2003.ijbcp20193171
Sarangi SC, Kaur N, Tripathi M. Need for pharmacoeconomic consideration of antiepileptic drugs monotherapy treatment in persons with epilepsy. Saudi Pharma J. 2020;28(10):1228–37. DOI: https://doi.org/10.1016/j.jsps.2020.08.013
Downloads
Published
How to Cite
Issue
Section
